Truist lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $36 from $39 and keeps a Buy rating on the shares. The company’s Q1 earnings included a more rapid than anticipated launch for Aqvesme, which comes as a welcome surprise to the firm, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)
- Is AGIO a Buy, Before Earnings?
- Agios Pharmaceuticals price target lowered to $41 from $44 at BofA
- Maintaining Buy on Agios: Mitapivat’s Risk-Adjusted Upside Despite Etavopivat Competition and Regulatory Uncertainty
- Agios Pharmaceuticals: Mitapivat’s Early-Mover Advantage and Diversified Pipeline Support Buy Rating Despite Emerging Sickle Cell Competition